SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementi... See more
Feb, 1, 2023
This will bring in billions of revenue and it will... See more
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Mar, 13, 2023
The introduction of Briumvi reduces the infusion t... See more
Mar, 8, 2023
In pooled post hoc analyses of ULTIMATE I and II, ... See more
BXRX
Baudax Bio Inc
-52.79%
$3.41 - $1.61
Feb 7th 2023 - Mar 21st 2023
Feb, 13, 2023
“We believe the use of BX1000, combined with our r... See more
Dec, 17, 2022
This could be significantly impactful for patients... See more
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”
Feb, 1, 2023
This will bring in billions of revenue and it will make the life quality longer for AD patients.
Jan, 29, 2023
This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.
Jan, 18, 2023
CURING LEUKEMIA isn't a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!
Jan, 11, 2023
$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete
Jan, 9, 2023
The high number of the patients that went into CMS (which is 80% complete) is reassuring.
Jan, 6, 2023
but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!
Dec, 30, 2022
but mostly new hope for all the families and patients with AZ.
Dec, 29, 2022
Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.
Mar, 13, 2023
The introduction of Briumvi reduces the infusion time to one hour, shortening the patients’ time spent in a clinical setting and allowing them to enhance their quality of life.”
Mar, 8, 2023
In pooled post hoc analyses of ULTIMATE I and II, ublituximab was associated with significant treatment benefit across multiple efficacy measures at Week 96 versus teriflunomide in participants who had not received prior DMT.
Feb, 21, 2023
ATNM just published very good data from their P3 trail which is great news for Acute myeloid leukemia patients.
Feb, 18, 2023
Remember that we are ultimately at the beginning of commercialization and quite possible the safest spot to be with the current facts on our superior Briumvi treatment and best pricing for market share penetration.
Feb, 13, 2023
beyond TG doing well, and us all making a ton of profit, i genuinely hope that this is the answer a lot of MS patients need to help them navigate & improve their illness.
Feb, 3, 2023
Getting the best available treatment for the lowest price is a no brainer.
Jan, 29, 2023
We have built what we consider to be a best-in-class team to support this launch, as well as a robust patient support program designed to aid in accessing BRIUMVI at all points through the treatment journey.
Jan, 21, 2023
They're FDA approved, have the best in class treatment, and is more affordable than the others.
Jan, 10, 2023
Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition
Jan, 6, 2023
$TGTX possibly the best therapy available for MS patients that exists today!
Feb, 13, 2023
“We believe the use of BX1000, combined with our reversal agent, BX3000, could make for precise control of timing under neuromuscular paralysis for surgical patients, which could result in time and cost savings for patients and hospitals alike.
Dec, 17, 2022
This could be significantly impactful for patients, surgeons, and anesthesiologists by enhancing safety, and possibly saving time and reducing costs related to delayed recovery from neuromuscular paralysis following surgical procedures.”
Dec, 9, 2022
It's a miracle drug for patients that suffer with cronic osteoarthritis.
Dec, 9, 2022
It is a game changer for heart patients and is being rapidly adopted by hospitals and doctors.